Eduardo Yáñez

Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial

Véronique Dièras, Hyo S. Han, Bella Kaufman et al. · The Lancet Oncology · 2020 · 321 citations · Full text

Medicine, Oncology, Pharmacology +10

Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial

Matthew J. Matasar, Marcelo Capra, Muhıt Özcan et al. · The Lancet Oncology · 2021 · 137 citations · Full text

Medicine, Immunology, Pharmacology +11

Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study.

Luis J. Villanueva-Rivera, Zarnie Lwin, Hyun Cheol Chung et al. · Journal of Clinical Oncology · 2021 · 69 citations

Medicine, Oncology, Pharmacology +15

LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.

Carlos Gomez‐Roca, Eduardo Yáñez, Seock‐Ah Im et al. · Journal of Clinical Oncology · 2021 · 68 citations

Medicine, Oncology, Pharmacology +12

Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Krishnansu S. Tewari, Nicoletta Colombo, Bradley J. Monk et al. · JAMA Oncology · 2023 · 59 citations · Full text

Medicine, Oncology, Pharmacotherapy +14